New PET tracer could reveal hidden cancer response
NCT ID NCT06414902
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests whether a special PET scan using a radioactive tracer called 18F-AraG can find tumors in people with esophageal cancer and predict how well they respond to chemoradiation. About 60 adults with untreated, locally advanced esophageal cancer will receive the tracer and be scanned. The main goal is to check safety, but researchers also hope to see if the scan can serve as a biomarker for treatment response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
18F-AraG (a radioactive tracer given by IV)
What this could lead to
If successful, this could give doctors a new way to see if chemoradiation is working in esophageal cancer patients, potentially guiding better treatment decisions.
What could go wrong
This is a very early Phase 1 study with only 60 people. The main goal is safety, not yet proving the scan predicts response. It may not work as hoped.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact